Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.40 | 14,156 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.30 | 2.50 | 2.40 | 2.40 | 2.40 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0095 | -2.53 | 13.04M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:24:51 | O | 1,700 | 2.4695 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/11/2024 | 10:57 | ALNC |  *Genedrive featured in UK Department for Business & Trade's genomics.. |
| 05/11/2024 | 10:53 | UK RNS | Genedrive PLC Department for Business and Trade feature |
| 04/11/2024 | 13:29 | UK RNS | Genedrive PLC Scottish Health Technology Group publications |
| 21/10/2024 | 14:22 | UK RNS | Genedrive PLC Director Declaration |
| 15/8/2024 | 09:39 | UK RNS | Genedrive PLC Director/PDMR Shareholding |
| 12/8/2024 | 06:00 | UK RNS | Genedrive PLC First UK commercial sales of the CYP2C19-ID Kit |
| 06/8/2024 | 13:36 | ALNC | Genedrive CEO leaves after less than a year; promotes CSO Miele to CEO |
| 06/8/2024 | 06:00 | UK RNS | Genedrive PLC Directorate Change |
| 31/7/2024 | 06:00 | UK RNS | Genedrive PLC NICE recommends CYP2C19-ID Kit in final guidance |
| 15/7/2024 | 18:36 | ALNC | EARNINGS AND TRADING: Genedrive in FDA boost; Bango revenue rises |
Genedrive (GDR) Share Charts1 Year Genedrive Chart |
|
1 Month Genedrive Chart |
Intraday Genedrive Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 21/11/2024 | 08:45 | Genedrive, A Game Changer for Point of Care Testing Market? | 9,986 |
| 18/11/2024 | 07:33 | GENEDRIVE MODERATED | 946 |
| 15/11/2024 | 08:33 | GENEDRIVE PLC | 740 |
| 01/9/2024 | 13:10 | TO DATE THEIR KITS HAVE REVENUES OF ONLY Ј100K.GET OUT!! | 38 |
| 08/8/2024 | 07:30 | Shares are poised to rebound very strongly | 1,248 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 08:24:53 | 2.47 | 1,700 | 41.98 | O |
| 08:15:45 | 2.30 | 43 | 0.99 | O |
| 08:15:45 | 2.30 | 1 | 0.02 | O |
| 08:15:45 | 2.50 | 4,500 | 112.50 | O |
| 08:15:45 | 2.30 | 172 | 3.96 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Genedrive Daily Update Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 2.40p.Genedrive currently has 543,141,481 shares in issue. The market capitalisation of Genedrive is £13,035,396. Genedrive has a price to earnings ratio (PE ratio) of -2.53. This morning GDR shares opened at 2.40p |
Posted at 18/11/2024 07:21 by m_night10 POLX Polarean Imaging 1.6p I fancy to fill the gap to 3.2p and head to 10p+. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025 Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars as used to trade at 100p and has made significant commercial progress since FDA approval. Massive takeover target and will be sold for 20p+ share price. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Posted at 14/11/2024 07:29 by m_night10 POLX Polarean Imaging about to break out above 2p soon. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.55p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Posted at 12/11/2024 19:02 by m_night10 POLX Polarean Imaging about to break out above 2p soon. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 155p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Posted at 12/11/2024 10:12 by hazl Good to see GDR share price fighting against the low start.That was due in part to the UT trade at close yesterday, in my opinion . IMO |
Posted at 12/11/2024 07:50 by m_night10 POLX Polarean Imaging will break out above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.55p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 08/11/2024 07:29 by m_night10 POLX about to break out above 2p. I see it as a steal for the FDA approvedXenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.65p and gap at over 3p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Similar set up to GDR before it filled it's gap. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR. |
Posted at 01/11/2024 06:34 by batiatus Let me remind you of some facts:-GDR isn't making any profits -GDR have only sold £100K worth of kits. -£100k is equivalent to 1250 units at £80 per kit -GDRs monthly expense is £400K, due to increase to £600K in 2025 -GDR is low on cash. They raised £5million in May 2024. -The current GDR bank will have less than £5million. -Cash will run out for GDR by May or June 2025 -GDR needs to sell 60,000 kits for the company to break even -It has taken GDR 9 months to sell 1250kits, or £100K worth of sales GDR is in a race against time to find buyers before their cash runs out. To-date, they haven't been doing too well. No one will buy unless the product is fully certified. |
Posted at 30/10/2024 22:34 by batiatus Let me remind you of some facts:-GDR isn't making any profits -GDR have only sold £100K worth of kits. -£100k is equivalent to 1250 units at £80 per kit -GDRs monthly expense is £400K, due to increase to £600K in 2025 -GDR is low on cash. They raised £5million in May 2024. -The current GDR bank will have less than £5million. -Cash will run out for GDR by May or June 2025 -GDR needs to sell 60,000 kits for the company to break even -It has taken GDR 9 months to sell 1250kits, or £100K worth of sales GDR is in a race against time to find buyers before their cash runs out. To-date, they haven't been doing too well. No one will but unless the product is fully certified. |
Posted at 17/10/2024 11:20 by batiatus Fact check:GDR is not making any profit. GDR annual expense is £4.8million £400K monthly cash burn, due to increase to £600K month in 2025 GDR to date have only managed £100K worth of sales. This equates to 1,250 units sold using £80 price mark. It means that GDR will need to sell 60,000 units just to break even. It has taken GDR 9 months to sell 1,250 units. Cash in the GDR bank will last to approximately June 2025. The rampers will tell you £5 million raised (this is their catch line) but the £5 million raised was in May 2024. GDR will have used another £1.6 million minimum since then. That means in the GDR bank there isn't £5 million. GDR is in a dire situation. They are racing against time to achieve more sales, before the money runs out. |
Posted at 28/9/2024 15:27 by batiatus "A lot on this forum do not want this company to become successful and that includes the above poster."A lot of garbage posted by people with no wisdom. From your comment above, you are implying the people who do not want the company to succeed have an impact on the company's performance from their comments. And you don't like it because it goes against your agenda of wanting the company to succeed. If that was the case, with equal effect, the rampers should also have influence on the share price movement from their comments. But the share price have consistently dropped and this tells you what. It tells you that if there were the power to influence the share price from commenting, then you rampers will all get A+. My comments are based on company's activities and supporting evidence with reference, such as promises made by the BOD, the business model, and finances. It's no secret that the current expenses far outweigh the income capacity, and the fact that GDR remains a no profit company. People can put on their rose tinted glasses all they like, but the share price never lies. It is sub 2p for various reasons. Putting the blame on the so-called derampers, the people stating facts, is just irresponsible, and irrelevant. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
